Cargando…
Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection
Background: Plasma levels of von Willebrand factor (VWF) are significantly elevated in patients with coronavirus disease 2019 (COVID-19). However, dynamic changes and prognostic value of this biomarker in hospitalized patients with COVID-19 have not been determined. Methods: A total of 124 patients...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672082/ https://www.ncbi.nlm.nih.gov/pubmed/38002786 http://dx.doi.org/10.3390/jcm12227174 |
_version_ | 1785149489064968192 |
---|---|
author | Zhang, Quan Bignotti, Antonia Yada, Noritaka Ye, Zhan Liu, Szumam Han, Zhe Zheng, X. Long |
author_facet | Zhang, Quan Bignotti, Antonia Yada, Noritaka Ye, Zhan Liu, Szumam Han, Zhe Zheng, X. Long |
author_sort | Zhang, Quan |
collection | PubMed |
description | Background: Plasma levels of von Willebrand factor (VWF) are significantly elevated in patients with coronavirus disease 2019 (COVID-19). However, dynamic changes and prognostic value of this biomarker in hospitalized patients with COVID-19 have not been determined. Methods: A total of 124 patients infected with SARS-CoV-2 were prospectively recruited for the study. Serial blood samples were obtained at the time of admission (D1), 3–4 days following standard-care treatments (D2), and 1–2 days prior to discharge or any time collected prior to death (D3). Plasma VWF antigen, ADAMTS13 antigen, and ADAMTS13 proteolytic activity, as well as the ratio of VWF/ADAMTS13 were determined, followed by various statistical analyses. Results: On admission, plasma levels of VWF in COVID-19 patients were significantly elevated compared with those in the healthy controls, but no statistical significance was detected among patients with different disease severity. Plasma ADAMTS13 activity but not its antigen levels were significantly lower in patients with severe or critical COVID-19 compared with that in other patient groups. Interestingly, the ratios of plasma VWF antigen to ADAMTS13 antigen were significantly higher in patients with severe or critical COVID-19 than in those with mild to moderate disease. More importantly, plasma levels of VWF and the ratios of VWF/ADAMTS13 were persistently elevated in patients with COVID-19 throughout hospitalization. Kaplan–Meier and Cox proportional hazard regression analyses demonstrated that an increased plasma level of VWF or ratio of VWF/ADAMTS13 at D2 and D3 was associated with an increased mortality rate. Conclusions: Persistent endotheliopathy, marked by the elevated levels of plasma VWF or VWF/ADAMTS13 ratio, is present in all hospitalized patients following SARS-CoV-2 infection, which is strongly associated with mortality. |
format | Online Article Text |
id | pubmed-10672082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106720822023-11-19 Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection Zhang, Quan Bignotti, Antonia Yada, Noritaka Ye, Zhan Liu, Szumam Han, Zhe Zheng, X. Long J Clin Med Article Background: Plasma levels of von Willebrand factor (VWF) are significantly elevated in patients with coronavirus disease 2019 (COVID-19). However, dynamic changes and prognostic value of this biomarker in hospitalized patients with COVID-19 have not been determined. Methods: A total of 124 patients infected with SARS-CoV-2 were prospectively recruited for the study. Serial blood samples were obtained at the time of admission (D1), 3–4 days following standard-care treatments (D2), and 1–2 days prior to discharge or any time collected prior to death (D3). Plasma VWF antigen, ADAMTS13 antigen, and ADAMTS13 proteolytic activity, as well as the ratio of VWF/ADAMTS13 were determined, followed by various statistical analyses. Results: On admission, plasma levels of VWF in COVID-19 patients were significantly elevated compared with those in the healthy controls, but no statistical significance was detected among patients with different disease severity. Plasma ADAMTS13 activity but not its antigen levels were significantly lower in patients with severe or critical COVID-19 compared with that in other patient groups. Interestingly, the ratios of plasma VWF antigen to ADAMTS13 antigen were significantly higher in patients with severe or critical COVID-19 than in those with mild to moderate disease. More importantly, plasma levels of VWF and the ratios of VWF/ADAMTS13 were persistently elevated in patients with COVID-19 throughout hospitalization. Kaplan–Meier and Cox proportional hazard regression analyses demonstrated that an increased plasma level of VWF or ratio of VWF/ADAMTS13 at D2 and D3 was associated with an increased mortality rate. Conclusions: Persistent endotheliopathy, marked by the elevated levels of plasma VWF or VWF/ADAMTS13 ratio, is present in all hospitalized patients following SARS-CoV-2 infection, which is strongly associated with mortality. MDPI 2023-11-19 /pmc/articles/PMC10672082/ /pubmed/38002786 http://dx.doi.org/10.3390/jcm12227174 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhang, Quan Bignotti, Antonia Yada, Noritaka Ye, Zhan Liu, Szumam Han, Zhe Zheng, X. Long Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection |
title | Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection |
title_full | Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection |
title_fullStr | Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection |
title_full_unstemmed | Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection |
title_short | Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection |
title_sort | dynamic assessment of plasma von willebrand factor and adamts13 predicts mortality in hospitalized patients with sars-cov-2 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672082/ https://www.ncbi.nlm.nih.gov/pubmed/38002786 http://dx.doi.org/10.3390/jcm12227174 |
work_keys_str_mv | AT zhangquan dynamicassessmentofplasmavonwillebrandfactorandadamts13predictsmortalityinhospitalizedpatientswithsarscov2infection AT bignottiantonia dynamicassessmentofplasmavonwillebrandfactorandadamts13predictsmortalityinhospitalizedpatientswithsarscov2infection AT yadanoritaka dynamicassessmentofplasmavonwillebrandfactorandadamts13predictsmortalityinhospitalizedpatientswithsarscov2infection AT yezhan dynamicassessmentofplasmavonwillebrandfactorandadamts13predictsmortalityinhospitalizedpatientswithsarscov2infection AT liuszumam dynamicassessmentofplasmavonwillebrandfactorandadamts13predictsmortalityinhospitalizedpatientswithsarscov2infection AT hanzhe dynamicassessmentofplasmavonwillebrandfactorandadamts13predictsmortalityinhospitalizedpatientswithsarscov2infection AT zhengxlong dynamicassessmentofplasmavonwillebrandfactorandadamts13predictsmortalityinhospitalizedpatientswithsarscov2infection |